Benzinga | Aug 11, 2020 04:58AM EDT

Chardan Capital Maintains Buy on Seres Therapeutics, Raises Price Target to $32.5

Chardan Capital maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and raises the price target from $12.5 to $32.5.